藥明康德(02359.HK)宣佈收購明捷醫藥60%股份
藥明康德(02359.HK)宣布成功收購明捷醫藥60%股份,收購完成後,明捷醫藥將成為藥明康德的控股子公司,並繼續專注於打造符合全球藥政法規的第三方藥物質量控制與分析實驗室。此次收購將進一步拓展藥明康德在藥物質量分析領域的能力與規模,同時,藥明康德亦將通過明捷醫藥靈活的商業策略與一站式的分析平台佈局,為多元化的客戶群體提供從註冊到生產放行的全方位藥物質量研究服務,助力提升相關行業標準,賦能客戶的新藥研發進程。(el/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.